Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Mannanoligosaccharides (MOS) are prebiotic compounds derived from the cell walls of yeast, particularly Saccharomyces cerevisiae. Their use to support or manage enteritis, especially in veterinary and animal nutrition contexts, is primarily based on their ability to modulate gut microbiota and immune responses. Several studies, particularly in poultry, swine, and aquaculture, have demonstrated that dietary supplementation with MOS can reduce the severity of enteric diseases, improve gut barrier function, and decrease pathogen colonization (such as Salmonella and E. coli). The mechanisms proposed include competitive exclusion of pathogenic bacteria by blocking their attachment to the gut lining, enhancement of beneficial gut flora, and modulation of local immune responses.

However, while there is laboratory and experimental animal evidence supporting the beneficial effects of MOS on gut health and inflammation, direct clinical evidence in humans or for the treatment of established enteritis is limited. Most studies focus on prevention and general gut health rather than treatment of acute or chronic enteritis. Therefore, the scientific validation is moderate (rated 2 out of 5), with more robust evidence in animals than humans. Clinical trials in humans are sparse, and MOS is not a standard therapy for enteritis in human medicine. As such, MOS is best viewed as a supportive or preventative measure rather than a primary treatment for enteritis, with evidence strongest in animal models.

More about Mannanoligosaccharides
More about Enteritis

Other ingredients used for Enteritis

Other health conditions supported by Mannanoligosaccharides

Products containing Mannanoligosaccharides